Kerim Erer
Research Subjects
Kerim Erer has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Rasim Şahin
Saglik Bilimleri Universitesi Kayseri Tip Fakultesi
3 shared publications - Olgu Erkin Çınar
Department of Hematology, Medipol Mega University Hospital, Istanbul Medipol University, 34810 Istanbul, Türkiye
2 shared publications Azade Kanat
Kayseri Sehir Egitim ve Arastirma Hastanesi
1 shared publication- Azade Kanat
Department of Infectious Diseases and Clinical Microbiology, Kilis Prof. Dr. Alaeddin Yavaşça State Hospital, Kilis, Türkiye
1 shared publication - Cihan Uysal
Department of Nephrology, Erciyes University School of Medicine, Kayseri, Turkey
1 shared publication Esma Eryılmaz Eren
Kayseri Sehir Egitim ve Arastirma Hastanesi
1 shared publication
Latest Publications
- Open Access
- 26 January 2026
- Published by Wiley
PRE- AND POST-TRANSPLANT HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN A PATIENT WITH RELAPSED ACUTE MYELOID LEUKEMIA
- 26 January 2026
- Published by Wiley
Open AccessPRE- AND POST-TRANSPLANT HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN A PATIENT WITH RELAPSED ACUTE MYELOID LEUKEMIA
- Open Access
- 22 December 2025
- Published by Wiley in Cancer Reports
- Vol. 8 (12) , e70432
Risk Factors for Infectious Adverse Events in Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Venetoclax Combinations: A Retrospective Single‐Centre Real‐World Experience
Background: Venetoclax‐based (ven) combinations have become a standard of care for acute myeloid leukemia (AML) patients ineligible for intensive chemotherapy. However, the associated risk of infectious adverse events (IAEs) remains a significant clinical concern. Aims: This study aimed to evaluate the incidence, characteristics, and risk factors for IAEs in newly diagnosed AML patients treated with venetoclax combinations in a real‐world setting. Methods and Results: We conducted a retrospective cohort study of AML patients treated with ven in combination with hypomethylating agents or low‐dose cytarabine (LDAC), with analyses performed on a treatment cycle basis. Clinical and laboratory data, including IAE characteristics, duration of neutropenia, and concomitant medications, were collected, and grade ≥ 2 IAEs were included according to CTCAE v5.0 criteria. The cohort included 143 treatment cycles of 43 patients, with a median neutropenia duration of 13 days (5–35). A total of 34 (23.8%) grade ≥ 2 IAEs occurred, with an incidence of 1 per 121 patient‐days. Multivariate analysis identified prolonged neutropenia (days, OR = 1.037, p = 0.005) and interacting concomitant medications (OR = 9.99, p < 0.001) as independent risk factors for IAEs. The rate of invasive fungal infections was as low as 3.5%, and the use of antifungal or antibacterial prophylaxis was not associated with a reduction in the rate of IAEs. Conclusion: IAEs remain a substantial risk in venetoclax‐treated AML patients, particularly during prolonged neutropenia and with concomitant drug interactions. Optimizing venetoclax regimens and careful management of interacting medications may mitigate these risks.
- 22 December 2025
- Published by Wiley in Cancer Reports
- Vol. 8 (12) , e70432
Open AccessRisk Factors for Infectious Adverse Events in Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Venetoclax Combinations: A Retrospective Single‐Centre Real‐World Experience
Background: Venetoclax‐based (ven) combinations have become a standard of care for acute myeloid leukemia (AML) patients ineligible for intensive chemotherapy. However, the associated risk of infectious adverse events (IAEs) remains a significant clinical concern. Aims: This study aimed to evaluate the incidence, characteristics, and risk factors for IAEs in newly diagnosed AML patients treated with venetoclax combinations in a real‐world setting. Methods and Results: We conducted a retrospective cohort study of AML patients treated with ven in combination with hypomethylating agents or low‐dose cytarabine (LDAC), with analyses performed on a treatment cycle basis. Clinical and laboratory data, including IAE characteristics, duration of neutropenia, and concomitant medications, were collected, and grade ≥ 2 IAEs were included according to CTCAE v5.0 criteria. The cohort included 143 treatment cycles of 43 patients, with a median neutropenia duration of 13 days (5–35). A total of 34 (23.8%) grade ≥ 2 IAEs occurred, with an incidence of 1 per 121 patient‐days. Multivariate analysis identified prolonged neutropenia (days, OR = 1.037, p = 0.005) and interacting concomitant medications (OR = 9.99, p < 0.001) as independent risk factors for IAEs. The rate of invasive fungal infections was as low as 3.5%, and the use of antifungal or antibacterial prophylaxis was not associated with a reduction in the rate of IAEs. Conclusion: IAEs remain a substantial risk in venetoclax‐treated AML patients, particularly during prolonged neutropenia and with concomitant drug interactions. Optimizing venetoclax regimens and careful management of interacting medications may mitigate these risks.
- Open Access
- 25 September 2025
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Nephrology
- Vol. 34 (4) , 1-7
The Impact of Citrate-Based Dialysis Solution on the Efficacy of Hemodialysis
Anticoagulation,citrate,dialysis solution,hemodialysis
- 25 September 2025
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Nephrology
- Vol. 34 (4) , 1-7
Open AccessThe Impact of Citrate-Based Dialysis Solution on the Efficacy of Hemodialysis
Anticoagulation,citrate,dialysis solution,hemodialysis
- Open Access
- 13 January 2025
- Published by Wiley
RISK FACTORS FOR INFECTIOUS ADVERSE EVENTS IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH VENETOCLAX COMBINATIONS: A RETROSPECTIVE SINGLE-CENTRE REAL-WORLD EXPERIENCE
Background: Venetoclax-based (ven) combinations have become a standard of care for acute myeloid leukemia (AML) patients ineligible for intensive chemotherapy. However, the associated risk of infectious adverse events (IAEs) remains a significant clinical concern. Aims: This study aimed to evaluate the incidence, characteristics, and risk factors for IAEs in newly diagnosed AML patients treated with venetoclax combinations in a real-world setting. Methods and Results: We conducted a retrospective cohort study of AML patients treated with ven in combination with hypomethylating agents or low-dose cytarabine (LDAC), with analyses performed on a treatment cycle basis. Clinical and laboratory data, including IAE characteristics, duration of neutropenia, and concomitant medications, were collected, and grade ≥2 IAEs were included according to CTCAE v5.0 criteria. The cohort included 143 treatment cycles of 43 patients, with a median neutropenia duration of 13 days (5–35). A total of 34 (23.8%) grade ≥2 IAEs occurred, with an incidence of 1 per 121 patient-days. Multivariate analysis identified prolonged neutropenia (days, OR=1.037, p=0.005) and interacting concomitant medications (OR=9.99, pConclusion: IAEs remain a substantial risk in venetoclax-treated AML patients, particularly during prolonged neutropenia and with concomitant drug interactions. Optimizing venetoclax regimens and careful management of interacting medications may mitigate these risks.
- 13 January 2025
- Published by Wiley
Open AccessRISK FACTORS FOR INFECTIOUS ADVERSE EVENTS IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH VENETOCLAX COMBINATIONS: A RETROSPECTIVE SINGLE-CENTRE REAL-WORLD EXPERIENCE
Background: Venetoclax-based (ven) combinations have become a standard of care for acute myeloid leukemia (AML) patients ineligible for intensive chemotherapy. However, the associated risk of infectious adverse events (IAEs) remains a significant clinical concern. Aims: This study aimed to evaluate the incidence, characteristics, and risk factors for IAEs in newly diagnosed AML patients treated with venetoclax combinations in a real-world setting. Methods and Results: We conducted a retrospective cohort study of AML patients treated with ven in combination with hypomethylating agents or low-dose cytarabine (LDAC), with analyses performed on a treatment cycle basis. Clinical and laboratory data, including IAE characteristics, duration of neutropenia, and concomitant medications, were collected, and grade ≥2 IAEs were included according to CTCAE v5.0 criteria. The cohort included 143 treatment cycles of 43 patients, with a median neutropenia duration of 13 days (5–35). A total of 34 (23.8%) grade ≥2 IAEs occurred, with an incidence of 1 per 121 patient-days. Multivariate analysis identified prolonged neutropenia (days, OR=1.037, p=0.005) and interacting concomitant medications (OR=9.99, pConclusion: IAEs remain a substantial risk in venetoclax-treated AML patients, particularly during prolonged neutropenia and with concomitant drug interactions. Optimizing venetoclax regimens and careful management of interacting medications may mitigate these risks.